INTRODUCTIONOvarian cancer is the second most frequently and the most deadly gynecological malignancy among women (Siegel, Miller, & Jemal, ). According to global statistics, approximately 238,700 new cases were clinically diagnosed with ovarian carcinoma, and it killed 151,900 cases in the world in 2008 (Torre et al., ). Due to difficulties of early detection, most patients with ovarian cancer are diagnosed with high stages of this disease. Five‐year survival rate at advanced‐stage ovarian carcinoma remains <20% (Heintz et al., ; Kaja et al., ). Serous histology is the most common ovarian cancer, and other histotypes include mucinous, endometrioid, clear cell tumors, and undifferentiated carcinomas, etc. (Vang, Shih Ie, & Kurman, ).Epigenetic modifications, especially DNA methylation, a commonly observed epigenetic change, have been noted in the initiation and progression of human cancer (Ghavifekr Fakhr, Farshdousti Hagh, Shanehbandi, & Baradaran, ; Huang et al., ; Ma, Wang, Zhang, & Gazdar, ). Aberrant promoter methylation of tumor suppressor genes (TSGs) is the most common methylation in many types of cancers (Smith et al., ; Yokoyama et al., ). O6‐methylguanine‐DNAmethyl‐transferase (MGMT), located on 10q26, a DNA repair gene, protects cells against the effects of alkylating agent chemotherapy by eliminating the alkylation of the O6 position of guanine (Esteller et al.,
Molecular Genetics & Genomic Medicine – Wiley
Published: Jan 1, 2018
Keywords: ; ; ;
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.
All for just $49/month
It’s easy to organize your research with our built-in tools.
All the latest content is available, no embargo periods.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud